GSA CAPITAL PARTNERS LLP

Position in FATE — Fate Therapeutics Inc

CIK 1362033 LONDON, X0

Position in FATE

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$358,657

+$149,285 QoQ

Shares Held

298,881

+39.9% QoQ

Ownership

0.256%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2022

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $101,563,069 across 163 Biotechnology names. FATE ranks #92 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$358,657	298,881	+39.9%	Shares	Sole	2026-05-08
2025-12-31	$209,372	213,645	-31.3%	Shares	Sole	2026-02-06
2025-09-30	$391,640	310,826	+21.1%	Shares	Sole	2025-11-07
2025-06-30	$287,528	256,722	-2.9%	Shares	Sole	2025-07-22
2024-06-30	$867,451	264,467	+405.9%	Shares	Sole	2024-08-15
2024-03-31	$383,727	52,279	+21.6%	Shares	Sole	2024-05-03
2023-12-31	$160,831	43,003	-83.0%	Shares	Sole	2024-02-16
2023-09-30	$537,269	253,429	+30.4%	Shares	Sole	2023-11-15
2023-06-30	$925,391	194,410	-7.6%	Shares	Sole	2023-08-14
2023-03-31	$1,199,337	210,410	+260.1%	Shares	Sole	2023-05-12
2022-12-31	$589,578	58,432	—	Shares	Sole	2023-02-13
No filing history on record for this holder in this stock.